Vertex Pharmaceuticals (VRTX) Common Equity (2009 - 2026)
Vertex Pharmaceuticals' quarterly Common Equity came in at $19.4 billion in Q1 2026, up 17.37% year-on-year from $16.5 billion in Q1 2025, and up 3.73% quarter-over-quarter from $18.7 billion in Q4 2025.
Vertex Pharmaceuticals has reported Common Equity for 18 years, with the latest figure at $19.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 17.37% year-over-year to $19.4 billion; the trailing twelve-month figure through Mar 2026 stood at $19.4 billion (up 17.37% YoY), and the FY2025 full-year result was $18.7 billion, up 13.75% from the prior year.
- Common Equity for Q1 2026 stood at $19.4 billion, up from $18.7 billion in the prior quarter.
- The five-year high for Common Equity was $19.4 billion in Q1 2026, with the low at $10.9 billion in Q1 2022.
- Average Common Equity over 5 years is $15.8 billion, with a median of $16.4 billion recorded in 2024.
- Year-over-year, Common Equity soared 37.75% in 2022 and slipped 11.05% in 2025.
- Tracing VRTX's Common Equity over 5 years: stood at $13.9 billion in 2022, then climbed by 26.36% to $17.6 billion in 2023, then slipped by 6.66% to $16.4 billion in 2024, then rose by 13.75% to $18.7 billion in 2025, then increased by 3.73% to $19.4 billion in 2026.
- The last three Common Equity figures came in at $19.4 billion (Q1 2026), $18.7 billion (Q4 2025), and $17.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 1.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.36 Bn |
| Dec 31, 2025 | 18.67 Bn |
| Sep 30, 2025 | 17.32 Bn |
| Jun 30, 2025 | 17.18 Bn |
| Mar 31, 2025 | 16.50 Bn |
| Dec 31, 2024 | 16.41 Bn |
| Sep 30, 2024 | 15.63 Bn |
| Jun 30, 2024 | 14.77 Bn |
| Mar 31, 2024 | 18.55 Bn |
| Dec 31, 2023 | 17.58 Bn |
| Sep 30, 2023 | 16.51 Bn |
| Jun 30, 2023 | 15.47 Bn |
| Mar 31, 2023 | 14.43 Bn |
| Dec 31, 2022 | 13.91 Bn |
| Sep 30, 2022 | 13.03 Bn |
| Jun 30, 2022 | 11.93 Bn |
| Mar 31, 2022 | 10.91 Bn |
| Dec 31, 2021 | 10.10 Bn |
| Sep 30, 2021 | 9.53 Bn |
| Jun 30, 2021 | 9.20 Bn |
| Mar 31, 2021 | 8.98 Bn |
| Dec 31, 2020 | 8.69 Bn |
| Sep 30, 2020 | 8.13 Bn |
| Jun 30, 2020 | 7.52 Bn |
| Mar 31, 2020 | 6.46 Bn |
| Dec 31, 2019 | 6.09 Bn |
| Sep 30, 2019 | 5.25 Bn |
| Jun 30, 2019 | 5.07 Bn |
| Mar 31, 2019 | 4.72 Bn |
| Dec 31, 2018 | 4.44 Bn |
| Sep 30, 2018 | 2.93 Bn |
| Jun 30, 2018 | 2.71 Bn |
| Mar 31, 2018 | 2.43 Bn |
| Dec 31, 2017 | 2.04 Bn |
| Sep 30, 2017 | 1.80 Bn |
| Jun 30, 2017 | 1.87 Bn |
| Mar 31, 2017 | 1.68 Bn |
| Dec 31, 2016 | 1.34 Bn |
| Sep 30, 2016 | 1.21 Bn |
| Jun 30, 2016 | 1.17 Bn |
| Mar 31, 2016 | 1.12 Bn |
| Dec 31, 2015 | 1.09 Bn |
| Sep 30, 2015 | 1.08 Bn |
| Jun 30, 2015 | 1.05 Bn |
| Mar 31, 2015 | 997.54 Mn |
| Dec 31, 2014 | 1.10 Bn |
| Sep 30, 2014 | 1.16 Bn |
| Jun 30, 2014 | 1.17 Bn |
| Mar 31, 2014 | 1.23 Bn |
| Dec 31, 2013 | 1.36 Bn |
| Sep 30, 2013 | 1.45 Bn |
| Jun 30, 2013 | 1.51 Bn |
| Mar 31, 2013 | 937.96 Mn |
| Dec 31, 2012 | 1.20 Bn |
| Sep 30, 2012 | 1.23 Bn |
| Jun 30, 2012 | 1.21 Bn |
| Mar 31, 2012 | 1.07 Bn |
| Dec 31, 2011 | 928.48 Mn |
| Sep 30, 2011 | 694.15 Mn |
| Mar 31, 2011 | 391.67 Mn |
| Dec 31, 2010 | 503.97 Mn |
| Sep 30, 2010 | 650.10 Mn |
| Jun 30, 2010 | 827.14 Mn |
| Mar 31, 2010 | 990.61 Mn |
| Dec 31, 2009 | 1.10 Bn |